Royalties payable Royalties Payable Represents the amount of royalties payable. Maturity of our operating lease liabilities Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amortization Expense Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Provision at U.S. federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount OPZELURA, ZYNZ and NIKTIMVO OPZELURA, ZYNZ And NIKTIMVO [Member] Represents information pertaining to OPZELURA (ruxolitinib) cream, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib. Cover [Abstract] Cover [Abstract] After 2029 Lessee, Operating Lease, Liability, to be Paid, after Year Five Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Schedule of Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes, and shares of Common Stock under the ESPP Stock Issued During Period Value Stock Options and Restricted Stock Units Exercised and Employee Stock Purchase Plan Value stock issued during the period as a result of the exercise of stock options and restricted stock units and the aggregate change in value for stock issued during the period as a result of employee stock purchase plan. Trading Symbol Trading Symbol Non-NEOs Non-NEOs [Member] $68.70 - $74.78 Range of Exercise Prices Three [Member] Represents the third range of exercise price. $115.19 - $134.38 Range of Exercise Prices Nine [Member] Represents the ninth range of exercise price. Share repurchase program, tender offer (in dollars per share) Share Repurchase Program, Tender Offer, Share Price Share Repurchase Program, Tender Offer, Share Price Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Line of Credit Facility [Table] Line of Credit Facility [Table] Income Tax Examination [Line Items] Income Tax Examination [Line Items] Accounts receivable Increase (Decrease) in Accounts Receivable Realized and unrealized gain (loss) on equity investments Realized and unrealized (gain) loss on equity investments Equity Securities, FV-NI, Gain (Loss) Net Income Per Share Earnings Per Share, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Land Land [Member] Unrealized gain (loss) on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Schedule of Inventory Schedule of Inventory [Table Text Block] Tabular disclosure of carrying amount of inventories as of the balance sheet date. Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Sale and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Income tax credits Deferred Tax Assets, Tax Credit Carryforwards Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Plan Name [Domain] Plan Name [Domain] United States U.S. UNITED STATES Inventory Inventory, Net [Abstract] Other assets, net Other Assets, Noncurrent Gross Carrying Amount Finite-Lived Intangible Assets, Gross Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Foreign-derived intangible income Effective Income Tax Rate Reconciliation, FDII, Amount Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Property, Plant and Equipment, Additions Property, Plant and Equipment, Additions Schedule of Activity Summarized Under all Stock Plans other than Options Schedule of RSU award and PSU activity under the 2010 Stock Plan [Table Text Block] Tabular disclosure represents the schedule of share based compensation other than stock options activity. Marketable securities-amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current Award Timing Method Award Timing Method [Text Block] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Office equipment Office Equipment [Member] Liability Liability [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Payment of contingent consideration Payment of Contingent Consideration The cash outflow with regard to the contingent consideration during the period. Measurement Frequency [Axis] Measurement Frequency [Axis] Revenue Recognition Revenue Recognition and Deferred Revenue [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Weighted average lease term, finance leases Finance Lease, Weighted Average Remaining Lease Term Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Payables and Accruals [Abstract] Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Clinical related costs Accrued Clinical Related Costs Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Stock compensation Stock Compensation Plans Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Expenses paid from assets Defined Benefit Plan, Expenses Paid From Assets Represents the amount of expenses paid from assets under defined benefit plan. Expected return on plan assets (as percent) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Accrued and other current liabilities Total accrued and other current liabilities Accrued Liabilities, Current Outstanding stock options and awards (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Less: discount Finance Lease, Liability, Undiscounted Excess Amount Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] $74.98 - $80.50 Range of Exercise Prices Four [Member] Represents the fourth range of exercise price. Asset Acquisition Asset Acquisition [Axis] Credit Facility [Domain] Credit Facility [Domain] Sales and marketing Accrued Marketing Costs, Current Additional milestone payments under the license agreement License Agreement Additional Milestone Payments Represents the additional milestone payments to be made under the license agreement. Christiana Stamoulis [Member] Christiana Stamoulis Total inventory Inventory Net Current and Noncurrent Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories. Goodwill Goodwill Tax withholdings related to restricted and performance share vesting Payment, Tax Withholding, Share-Based Payment Arrangement Share repurchase program, authorized, amount Share Repurchase Program, Authorized, Amount Inventory Inventory Disclosure [Text Block] Non-employee Director Non-employee Director Represents non-employee directors who may be eligible to receive awards under the share-based compensation plans. Options Share-Based Payment Arrangement, Option [Member] Depreciation expense including amortization expense of leasehold improvements Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Xencor Xencor [Member] Xencor Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accrued taxes Accrued Income Taxes, Current Weighted average discount rate, finance leases Finance Lease, Weighted Average Discount Rate, Percent 2025 Finance Lease, Liability, to be Paid, Year One Amortized Cost Debt securities (government) Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Award Type [Axis] Award Type [Axis] Schedule of Stock Options Outstanding and Exercisable by Exercise Price Range Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Basic Net Income Per Share Earnings Per Share, Basic [Abstract] Deferred tax asset Asset Acquisition, Deferred Tax Asset Asset Acquisition, Deferred Tax Asset API and Work-in-process Inventory, Work in Process, Net of Reserves Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total liabilities Liabilities Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Weighted- Average Useful Lives (Years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Investment owned (in shares) Investment Owned, Balance, Shares Operating lease liabilities, current Operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Research and development - external Research And Development Expense, External Research And Development Expense, External Reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Net operating loss carry forwards Deferred Tax Assets, Operating Loss Carryforwards Laboratory equipment Equipment [Member] Property and Equipment, gross Property, Plant and Equipment, Gross Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Plan participants' contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and Development Expense Research and Development Expense [Member] Reductions due to lapse of applicable statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Diluted (in shares) Weighted average shares used to compute diluted net income per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Accrued Liabilities Accrued Liabilities [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other research and development Other Research and Development Expense Total stockholders’ equity Beginning Balance Ending Balance Equity, Attributable to Parent Total gross deferred tax assets Deferred Tax Assets, Gross Sheila Denton [Member] Sheila Denton Less than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Litigation Case [Axis] Litigation Case [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Acquisition-related contingent consideration Deferred Tax Assets, Contingent Consideration Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent consideration. Letters of credit outstanding, amount Letters of Credit Outstanding, Amount Percentage of profit (losses) Percentage of Profits (Losses) Represents the percentage of profits (losses). Selling, general and administrative Selling, General and Administrative Expense Defined contribution expense Defined Contribution Plan, Cost Cost of Sales Cost of Sales [Member] Product revenues, net Product [Member] Sale of Stock [Domain] Sale of Stock [Domain] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Dilutive stock options and awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Stock Incentive Plan 2010 Stock Incentive Plan 2010 Represents the 2010 Stock Incentive Plan adopted by the board of directors. 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Dividend yield (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Acquisitions accounted for as research and development expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Document Type Document Type Sale of equity investments Proceeds from Sale of Long-Term Investments Actuarial loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Purchases of marketable securities Payments to Acquire Marketable Securities Development, Regulatory and Commercialization Milestones Development, Regulatory and Commercialization Milestones [Member] Represents development regulatory and commercialization milestones. Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Dutch Auction Tender Offer Dutch Auction Tender Offer [Member] Dutch Auction Tender Offer Schedule of Estimated Aggregate Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Inventory, Current [Table] Inventory, Current [Table] Lease liabilities Assets and Liabilities, Lessee [Abstract] Maximum Maximum [Member] Number Outstanding (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Change in uncertain tax positions Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Net Carrying Amount Finite-Lived Intangible Assets, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current ICLUSIG ICLUSIG Represents information pertaining to ICLUSIG, a kinase inhibitor. Number of independent programs License Agreement, Maximum Number Of Independent Programs Represents the maximum number of independent programs encompassed under the collaboration agreement. Statistical Measurement [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Name Outstanding Recovery, Individual Name Revenues Disaggregation of Revenue [Line Items] Schedule of Antidilutive Securities Excluded from the Diluted Net (Loss) Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Title and Position [Axis] Title and Position [Axis] Accrued and other liabilities Accrued Liabilities and Other Liabilities Achievement of Milestone [Domain] Achievement of Milestone [Domain] Different categories of achievement of milestones. Award Timing Predetermined Award Timing Predetermined [Flag] $80.56 - $83.58 Range of Exercise Prices Five [Member] Represents the fifth range of exercise price. In Process Research and Development - INCB000547 In Process Research and Development - INCB000547 [Member] In Process Research and Development - INCB000547 Investment, Name [Axis] Investment, Name [Axis] Restricted cash Restricted Cash, Noncurrent Percentage of reverse royalty Percentage of Reverse Royalties On Sale of Future Products Represents the percentage of reverse royalties on sale of future products. Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Diluted (in dollars per share) Diluted net income per share (in dollars per share) Earnings Per Share, Diluted Expected benefit payments Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Changes to the carry amount of goodwill Goodwill, Period Increase (Decrease) Counterparty Name [Domain] Counterparty Name [Domain] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Advance written notice period (in days) License Agreement, Advance Written Notice Period License Agreement, Advance Written Notice Period State State and Local Jurisdiction [Member] Current provision for income taxes Current Income Tax Expense (Benefit) Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Payment obligation breach, written notice period (in days) License Agreement, Written Notice Period For Payment Obligation Breach, License Agreement, Written Notice Period For Payment Obligation Breach Ownership [Axis] Ownership [Axis] Percentage of units vesting at the end of each calendar year (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Non-current liabilities Asset Acquisition, Noncurrent Liabilities Asset Acquisition, Noncurrent Liabilities Other Intangible Assets, net Intangible Assets, Finite-Lived, Policy [Policy Text Block] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Commercialization Milestones Commercialization Milestones [Member] Represents information pertaining to certain commercialized events on the basis of which certain milestones are achieved. Income tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Sales and marketing Selling and Marketing Expense Other Deferred Tax Liabilities, Other Profit sharing Collaboration Agreement Profit Sharing Percentage Represents the percentage of profits and losses shared under the collaboration agreement. Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Provision for income taxes Total provision for income taxes Income Tax Expense (Benefit) Interest cost Interest cost Defined Benefit Plan, Interest Cost Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Vesting period of recognition of the unrecognized compensation cost of nonvested awards (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition OLUMIANT OLUMIANT [Member] Baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). Total revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax Payments for intangible assets Payments to Acquire Intangible Assets Upfront payment received under license agreement License Agreement, Upfront Payment Received Represents the upfront payment received under the license agreement. Capitalized milestone payments Capitalized Milestone Payments [Member] Capitalized Milestone Payments Customer A, B, C D, E and F Customer A, B, C D, E and F [Member] Represents information pertaining to the aggregate list of concentration customers. Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Additional authorization (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued compensation Employee-related Liabilities, Current Total U.S. GAAP Consideration (net of compensation expense) Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Other intangible assets, net Other Intangible Assets, Net Barry Flannelly [Member] Barry Flannelly Other Countries Other Countries [Member] Other Countries Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Period of lower average per unit cost of materials (in months) Period Of Deviation From Average, Cost Of Goods Sold Represents the length of time in which cost of goods sold will deviate from average due to unusual and/or infrequent conditions. Sales Revenue Goods Services Net Sales Revenue Goods Services Net [Member] Aggregate revenue during the period from the sale of goods and services in the normal course of business, after deducting returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation. Agenus Agenus [Member] Represents details pertaining to Agenus with whom we have entered into a License, Development and Commercialization Agreement. Entity Address, State or Province Entity Address, State or Province Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Net prior service costs Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Transfer of benefits net of payments from fund Defined Benefit Plan Plan Assets Transfer of Benefits Net Amount of benefit transfers received by defined benefit plan which increase plan assets. Financial Instruments [Domain] Financial Instruments [Domain] Vesting [Domain] Vesting [Domain] Grant date value of shares outstanding at the beginning of the period (in USD per share) Grant date value of shares at the end of the period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Schedule of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Unpaid excise tax on repurchase of common stock Excise Tax On Repurchase Of Common Stock Incurred But Not Yet Paid Excise Tax On Repurchase Of Common Stock Incurred But Not Yet Paid Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Restatement Determination Date Restatement Determination Date Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Customer C Customer C [Member] Represents information pertaining to the customer C. Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Concentration Risk [Table] Concentration Risk [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans Exercise Price Range, Outstanding Options [Abstract] Share-based Compensation, Shares Authorized under Stock Option Plans Exercise Price Range, Outstanding Options [Abstract] Exercise Price Range [Domain] Exercise Price Range [Domain] Schedule of Fair Value of Liabilities Measured on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Other non-current assets Asset Acquisition, Other Non Current Assets Asset Acquisition, Other Non Current Assets Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Total liabilities Financial Liabilities Fair Value Disclosure Net Income Per Share Earnings Per Share [Text Block] Costs, expenses and other: Costs and Expenses [Abstract] $52.94 - $61.76 Range of Exercise Prices One [Member] Represents the first range of exercise price. Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Total Defined Benefit Plan Expected Future Benefit Payments Total The total amount of benefits from a defined benefit plan expected to be paid . Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Schedule of Finance Lease, Liability, Fiscal Year Maturity Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Weighted Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price PEO PEO [Member] Name Trading Arrangement, Individual Name Unfunded liability, end of year Defined Benefit Plan, Funded (Unfunded) Status of Plan Asset acquisition, compensation expense Asset Acquisition, Compensation Expense Asset Acquisition, Compensation Expense Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Pension liability, beginning of year Pension liability, end of year Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Inventory incurred prior to FDA approval Inventory, Recorded as Research and Development Expense Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories recorded as research and development expense. Entity Public Float Entity Public Float Options exercisable and vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Commitment fee Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Benefit obligation, beginning of the year Benefit obligation, end of the year Defined Benefit Plan, Benefit Obligation Milestone and contract revenues Milestone And Contract Revenues [Member] Represents information pertaining to milestone and contract revenues. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Shares reserved for future issuance related to stock plans (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Less valuation allowance for deferred tax assets Deferred Tax Assets, Valuation Allowance Weighted-average fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant Date Fair Value The weighted-average grant-date fair value of awards granted during the reporting period. Profit (loss) sharing ratio Collaboration Agreement Profit Loss Sharing Ratio Ratio of sharing profit and losses under the collaboration agreement. Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Grant Date Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Marketable securities-allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Conversion ratio Subsidiary Stock, Conversion Ratio Number of parent common shares issuable upon conversion for each share of subsidiary stock to be converted. PEMAZYRE Royalty Revenues PEMAZYRE Royalty Revenues [Member] PEMAZYRE Royalty Revenues Estimated Fair Value Total Debt Securities, Available-for-Sale, Excluding Accrued Interest Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward] No definition available. Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] TABRECTA Royalty Revenues TABRECTA Royalty Revenues [Member] Represents information pertaining to TABRECTA royalty revenues, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14). Common Stock Common Stock [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Roll Forward of Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Options Exercisable Share-based Compensation, Shares Authorized under Stock Option Plans Exercise Price Range, Exercisable Options [Abstract] Share-based Compensation, Shares Authorized under Stock Option Plans Exercise Price Range, Exercisable Options [Abstract] Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key JAKAFI JAKAFI [Member] Represents information pertaining to JAKAFI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold within the United State of America. Other segment items Segment Reporting, Other Segment Item, Amount Accrued and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued OLUMIANT Royalty Revenues OLUMIANT Royalty Revenues Represents information pertaining to OLUMIANT royalty revenues, a treatment of adults with moderately-to-severely active rheumatoid arthritis. Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Stockholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Segment Information Segment Reporting Disclosure [Text Block] Stock compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Measurement Basis [Axis] Measurement Basis [Axis] Royalty payments on future global net sales (as percent) Percentage Of Royalty Rate Payments Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. Intangible Assets, Net Intangible Assets, Net (Excluding Goodwill) [Abstract] Title Trading Arrangement, Individual Title Schedule of Income (Loss) from Operations Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Balance at beginning of year Balance at end of year Unrecognized Tax Benefits Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] City Area Code City Area Code Asset acquisition, consideration transferred, transaction cost Asset Acquisition, Consideration Transferred, Transaction Cost Current liabilities: Liabilities, Current [Abstract] Auditor Location Auditor Location Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Repurchase of common stock Payments for Repurchase of Common Stock Organization and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves (Accumulated deficit) retained earnings Retained Earnings (Accumulated Deficit) Accounts payable and accrued expenses Asset Acquisition, Accounts Payable And Accrued Expenses Asset Acquisition, Accounts Payable And Accrued Expenses License agreements Related Party Transaction [Line Items] Inventory Increase (Decrease) in Inventories General and administrative General and Administrative Expense Currency translation adjustment Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation $95.54 - $113.64 Range of Exercise Prices Eight [Member] Represents the eighth range of exercise price. Realized and unrealized loss on equity investments Realized and unrealized gain (loss) on equity investments Equity Securities, FV-NI, Unrealized Gain (Loss) Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Present value of lease liabilities Operating Lease, Liability Underlying Securities Award Underlying Securities Amount Performance Shares Performance Shares [Member] 2029 Finance Lease, Liability, to be Paid, Year Five Amendment Flag Amendment Flag Plan participants' contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] MacroGenics MacroGenics [Member] Represents details pertaining to MacroGenics with whom we have entered into an exclusive global collaboration and license agreement. Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Amortization on our finance lease right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Proceeds from sale of equity securities, FV-NI Proceeds from Sale of Equity Securities, FV-NI Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Shares divested (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Customer F Customer F [Member] Customer F Marketable securities—available-for-sale (amortized cost $469,917 and $442,816 as of December 31, 2024 and 2023 respectively; allowance for credit losses $0 as of December 31, 2024 and 2023) Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Payments made during the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Entity Address, Postal Zip Code Entity Address, Postal Zip Code Advertising expenses Advertising Expense Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Tafasitamab Product and Service Tafasitamab Product and Service [Member] Tafasitamab Product and Service Baker Entities Share Repurchase Program Baker Entities Share Repurchase Program [Member] Baker Entities Share Repurchase Program Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Customer E Customer E [Member] Customer E Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop Percentage Funding on Cost on Possible Election of Co-development of Compounds Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications. Amount recognized and received for the achievement of a predefined milestone License Agreement, Amount Recognized and Received for Achievement of a Predefined Milestone Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement. Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Cancelled (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Employee Stock Employee Stock [Member] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Accounts payable Increase (Decrease) in Accounts Payable Stock based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Proceeds from issuance of common stock under stock plans Proceeds from Stock Plans Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Schedule of Assets and Liabilities, Lessee Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Payment of finance lease liabilities Cash paid for financing lease liabilities in financing cash flows Finance Lease, Principal Payments License Agreements License Agreements License Agreements Basic net income Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Translation (gain) loss Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Shares used in computing net income per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Advertising Expenses Advertising Cost [Policy Text Block] Payments to acquire property, plant, and equipment Payments to Acquire Property, Plant, and Equipment Other liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 16) Commitments and Contingencies Stock Compensation and Long Term Incentive Plans Share-Based Payment Arrangement [Policy Text Block] Royalties Accrued Royalties, Current Percentage of additional royalties Percentage of Net Sales Pertaining to Additional Royalties Represents the percentage of net sales attributable to additional royalties. Schedule of Reconciliation of Income Taxes at the U.S. Federal Statutory Rate to the (Benefit) Provision for Income Taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Acquisitions Asset Acquisition [Text Block] Termination Date Trading Arrangement Termination Date Anti-dilutive securities Earnings Per Share, Diluted, Other Disclosure [Abstract] Related Party Transaction [Table] Related Party Transaction [Table] Fair value of financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Deferred tax assets: Deferred Tax Assets, Gross [Abstract] 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Issuance of shares of Common Stock for services rendered (in shares) Stock Issued During Period, Shares, Issued for Services Other current liabilities Asset Acquisition, Other Current Liabilities Asset Acquisition, Other Current Liabilities Escient Escient Pharmaceuticals [Member] Escient Pharmaceuticals Net income Net income Net income Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] 2030-2034 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] (Profit) and loss sharing under collaboration agreements Collaboration Loss (Profit) Sharing Expense Collaboration Loss (Profit) Sharing Expense Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Equity Investments Equity Securities, FV-NI [Policy Text Block] Equity Securities, FV-NI Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Regulatory Milestone Regulatory Milestone [Member] Regulatory Milestone Federal Current Federal Tax Expense (Benefit) Customer B Customer B [Member] Represents information pertaining to the customer B. Effect of exchange rates on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Name Forgone Recovery, Individual Name Weighted average lease term, operating leases Operating Lease, Weighted Average Remaining Lease Term Deferred income taxes Increase (Decrease) in Deferred Income Taxes Other, net Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Commitments Line of Credit Facility [Line Items] Payment to acquire license agreement Payments To Acquire License Agreement Payments To Acquire License Agreement Reductions related to prior periods tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions ZYNYZ ZYNYZ [Member] ZYNYZ Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cost of product revenues (including definite-lived intangible amortization) Cost of Revenue Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable Accounts Receivable [Member] JAKAVI Royalty Revenues JAKAVI Royalty Revenues [Member] Represents information pertaining to JAKAVI royalty revenues, an oral Janus associate kinase (JAK) inhibitor sold within the United State of America. $90.56 - $95.34 Range of Exercise Prices Seven [Member] Represents the seventh range of exercise price. Litigation Case [Domain] Litigation Case [Domain] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Inventory Inventories-noncurrent Inventory, Noncurrent Additions related to acquisitions Unrecognized Tax Benefits, Increase Resulting from Acquisition Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Reportable Segment Reportable Segment [Member] Reportable Segment Options cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Customer A Customer A [Member] Represents information pertaining to the customer A. Consolidated leverage ratio Line Of Credit Facility Covenant Terms Consolidated Total Leverage Ratio Maximum Line Of Credit Facility Covenant Terms Consolidated Total Leverage Ratio Maximum MorphoSys AG MorphoSys AG [Member] Represents member information pertaining to MorphoSys AG. Entity Filer Category Entity Filer Category Novartis Novartis [Member] Represents details pertaining to Novartis with whom we have entered into a Collaboration and License Agreement. Contingencies Loss Contingencies [Line Items] Number Exercisable (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Projected cash flows period (in years) Fair Value Inputs Cash Flows Estimated Period Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value. Statistical Measurement [Domain] Statistical Measurement [Domain] Unrealized (Losses) Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Syndax Syndax [Member] Represents member information pertaining to Syndax Pharmaceuticals Inc. Other current liabilities Other Liabilities, Current Tax benefit if unrecognized tax benefits were realized Unrecognized Tax Benefits that Would Impact Effective Tax Rate All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Calculation of Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Tax credit carryforward Tax Credit Carryforward, Amount Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] $138.52 - $138.52 Range of Exercise Prices Ten [Member] Represents the tenth range of exercise price. Income taxes paid Income Taxes Paid, Net Released (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period Represents the number of shares of employee compensation programs, other than options, released during the period. Share repurchase, fees and expenses Share Repurchase, Fees and Expenses Share Repurchase, Fees and Expenses Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Operating lease right-of-use assets Operating lease right-of-use assets Contractual agreement that stipulates the lessee pay the lessor for use of an asset under operating lease. Upfront payment under license agreement License Agreement Upfront Payment Amount Paid Represents the amount of the upfront payment made under the license agreement. Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Rate of compensation increase (as percent) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Research and development credit carryforwards Research Tax Credit Carryforward [Member] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Expense related to our operating leases Operating Lease, Cost Remaining shares available (in shares) Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Interest expense on finance lease liabilities Finance Lease, Interest Expense Audit Information [Abstract] Audit Information Advertising Expenses Marketing and Advertising Expense [Abstract] Employer service cost Service cost Defined Benefit Plan, Service Cost Entity Tax Identification Number Entity Tax Identification Number Additions related to prior periods tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Number of shares awarded for each RSU (in shares) Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Per Restricted Stock Units Represents the number of shares awarded for each restricted share units. Foreign Deferred Foreign Income Tax Expense (Benefit) Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Rate of compensation increase (as percent) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Plan Name [Axis] Plan Name [Axis] After 2029 Finance Lease, Liability, to be Paid, after Year Five Equity Components [Axis] Equity Components [Axis] Total lease cash payments Finance Lease, Liability, to be Paid $62.08 - $68.62 Range of Exercise Prices Two [Member] Represents the second range of exercise price. Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Accounts Receivable Accounts Receivable [Policy Text Block] Weighted Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price PEMAZYRE PEMAZYRE Represents information pertaining to PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Measurement Input, Cap Rate Measurement Input, Cap Rate [Member] Customer D Customer D [Member] Represents information pertaining to the customer D. Total costs, expenses and other Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Diluted Net Income Per Share Earnings Per Share, Diluted [Abstract] Geographical [Axis] Geographical [Axis] Net deferred tax assets Deferred Tax Assets, Net 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Repurchase of common stock Repurchase of common stock Stock Repurchased During Period, Value Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Current Loss contingency accrual Loss Contingency Accrual Summary of marketable security portfolio Debt Securities, Available-for-Sale [Line Items] Issuance of shares of Common Stock under the ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Unrecognized compensation cost for nonvested option Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Foreign Current Foreign Tax Expense (Benefit) Current assets: Assets, Current [Abstract] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Changes to carrying amount of goodwill Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Upfront and immediate milestone payment to be received under license agreement License Agreement, Upfront Payment and Immediate Milestone Payment to be Received Represents the upfront and immediate milestone payment received under the license agreement. Security Exchange Name Security Exchange Name Interest rate margin Debt Instrument, Basis Spread on Variable Rate Purchase of long term investments Payments to Acquire Long-Term Investments Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Capital expenditures Payments to Acquire Other Productive Assets Options, RSUs and PSUs granted and issuance of shares for services rendered (in shares) Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Granted Number of shares granted under an established share-based compensation plan. State Current State and Local Tax Expense (Benefit) Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Marketable Securities Portfolio Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Leased assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Variable Interest Entities Variable Interest Entities Abstract n/a Common stock, shares issued (in shares) Common Stock, Shares, Issued Net loss (gain) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Entity [Domain] Entity [Domain] Aggregate principal amount Line of Credit Facility, Maximum Borrowing Capacity Percentage of concentration risk Concentration Risk, Percentage Computer equipment Computer Equipment [Member] Investment in Syndax Investment in Syndax Represents investment information pertaining to Syndax Pharmaceuticals Inc. Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accounts receivable Accounts Receivable, after Allowance for Credit Loss Europe Europe [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Intangibles, net Deferred Tax Assets, Goodwill and Intangible Assets Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Syndax Syndax Represents member information pertaining to Syndax Pharmaceuticals Inc. Entity Voluntary Filers Entity Voluntary Filers Amortization of actuarial losses Defined Benefit Plan, Amortization of Gain (Loss) Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Interest expense Interest Expense, Nonoperating Deferred provision for income taxes Deferred Income Tax Expense (Benefit) Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Discount rate (as percent) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Swiss income tax credit carryforwards Foreign Income Tax Credit Carryforward [Member] Foreign Income Tax Credit Carryforward Schedule of Valuation Assumptions Used for Valuation of Fair Value of Stock Compensation Granted Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Other comprehensive (loss) income Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Fair Value, Recurring Fair Value, Recurring [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair value of plan assets, beginning of year Fair value of plan assets, end of year Defined Benefit Plan, Plan Assets, Amount Total lease liabilities Operating And Finance Lease Liability Present value of lessee's discounted obligation for lease payments from operating and finance lease. Debt instrument, credit spread adjustment on variable rate Debt Instrument, Credit Spread Adjustment On Variable Rate Debt Instrument, Credit Spread Adjustment On Variable Rate GVHD GVHD [Member] Represents information pertaining to GVHD, an Graft-Versus-Host Disease field. Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Increase in maximum revolving commitments Line of Credit Facility, Additional Borrowing Capacity Additional borrowing capacity under the credit facility with consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Shares acquired, average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share In Process Research and Development - INCB000262 In Process Research and Development - INCB000262 [Member] In Process Research and Development - INCB000262 Document Annual Report Document Annual Report Research and development - internal Research And Development Expense, Internal Research And Development Expense, Internal 2027 Finance Lease, Liability, to be Paid, Year Three Exercise price, lower range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Average risk-free interest rates Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Amortization expense Amortization of Intangible Assets Acquisition-Related Contingent Consideration Business Combination Contingent Consideration [Policy Text Block] Disclosure of accounting policy for acquisition related contingent consideration. Non-U.S. Non-US [Member] Revenues: Revenues [Abstract] License agreement, amount payable for waiver of certain future milestones payment License Agreement, Amount Payable For Waiver Of Certain Future Milestones License Agreement, Amount Payable For Waiver Of Certain Future Milestones Current Fiscal Year End Date Current Fiscal Year End Date Less: discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Name PEO Name Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Non-cash compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Deferred income tax asset Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life ARIAD ARIAD Represents information pertaining to ARIAD Pharmaceuticals. Additional Paid-in Capital Additional Paid-in Capital [Member] Finance lease liabilities Finance lease liabilities, noncurrent Finance Lease, Liability, Noncurrent Baker Entities Baker Entities [Member] Baker Entities Prepaid expenses and other current assets Asset Acquisition, Prepaid Expenses And Other Current Assets Asset Acquisition, Prepaid Expenses And Other Current Assets Employee Benefit Plans Retirement Benefits [Text Block] Concentrations of Credit Risk and Current Expected Credit Losses Concentration Risk Disclosure [Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Title and Position [Domain] Title and Position [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2028 Finance Lease, Liability, to be Paid, Year Four Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Number of operating segments Number of Operating Segments Significant components of deferred tax assets and liabilities Components of Deferred Tax Assets [Abstract] Switzerland SWITZERLAND Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Valuation input (as a percent) Business Combination, Contingent Consideration, Liability, Measurement Input Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Number of employee working hours per week for eligibility to participate in the plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Working Hours Per Week Required to Participate under Plan Represents the number of hours that a part-time or regular full-time employee must work per week to participate under the plan. Net deferred tax assets Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Share-based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Supplemental Schedule of Cash Flow Information Supplemental Cash Flow Information [Abstract] Equity securities, FV-NI Equity Securities, FV-NI Diluted net income Net Income (Loss) Available to Common Stockholders, Diluted Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Capitalized research and development Deferred Tax Asset, In-Process Research and Development Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Auditor Firm ID Auditor Firm ID Income from operations Operating Income (Loss) Variable Rate [Domain] Variable Rate [Domain] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Number of reportable segments Number of Reportable Segments Total liabilities and stockholders’ equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Marketable Securities-Available-for-Sale Marketable Securities, Policy [Policy Text Block] Incyte Incyte [Member] Represents member information pertaining to Incyte. 2026 Finance Lease, Liability, to be Paid, Year Two Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Leased assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Concentrations of Credit Risk Concentration of Credit Risk [Abstract] Concentration of Credit Risk [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Measurement Input Type [Axis] Measurement Input Type [Axis] Individual: Individual [Axis] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] $83.83 - $90.00 Range of Exercise Prices Six [Member] Represents the sixth range of exercise price. Options cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Average expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventory Inventories - current Inventory, Net Product and Service [Axis] Product and Service [Axis] Property and equipment, net Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Schedule of Share Activity Schedule of Stockholders Equity [Table Text Block] Building and leasehold improvements Building and leasehold improvements [Member] Represents information relating to building and leasehold improvements. Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Current Expected Credit Losses Credit Loss, Financial Instrument [Policy Text Block] Minimum Minimum [Member] Product royalty revenues Royalty [Member] Adoption Date Trading Arrangement Adoption Date Related Party Transactions [Abstract] Payments for asset acquisitions Payments For Asset Acquisitions Payments For Asset Acquisitions Debt securities (government) Debt securities (government) Debt securities issued by government or corporate business, banks and other entities with a promise of repayment. U.S. Centers for Medicare and Medicaid Services U.S. Centers for Medicare and Medicaid Services [Member] U.S. Centers for Medicare and Medicaid Services Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Inventory [Line Items] Inventory [Line Items] Exercise Price Award Exercise Price Schedule of Significant Components of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Asset Acquisition [Table] Asset Acquisition [Table] Board of Directors Approved Share Repurchase Program Board Of Directors Approved Share Repurchase Program [Member] Board Of Directors Approved Share Repurchase Program Arrangement Duration Trading Arrangement Duration Net operating loss carryforwards Operating Loss Carryforwards Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Options, RSUs and PSUs cancelled (in shares) Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Canceled Number of shares canceled under an established share-based compensation plan. Stockholders’ equity: Equity, Attributable to Parent [Abstract] Federal Domestic Tax Jurisdiction [Member] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Share repurchase program, excise tax Share Repurchase Program, Excise Tax 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Present value of lease liabilities Finance Lease, Liability All Individuals All Individuals [Member] Variable Rate [Axis] Variable Rate [Axis] Credit Concentration Risk Credit Concentration Risk [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Translation (loss) gain Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) JAKAVI JAKAVI [Member] Represents information pertaining to JAKAVI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold outside the United State of America. Interest income Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Milestone payment made under license agreement License Agreement Milestone Payment Amount Paid Represents the amount of the milestone payment made under the license agreement. Accrued and Other Current Liabilities Accrued And Other Current Liabilities [Member] Primary financial statement caption encompassing accrued and other current liabilities. Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Schedule of Changes Recognized in Other Comprehensive Income (Loss) Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Changes in plan assets Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Currency translation adjustment Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Sales allowances Provision for Loss on Contracts Liability Class [Axis] Liability Class [Axis] Released (in USD per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period, Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period, Weighted Average Grant Date Fair Value Tax Credit Carryforward Tax Credit Carryforward [Line Items] Stock options outstanding Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Stock repurchased (in shares) Stock Repurchased During Period, Shares Expiration period (in years) License Agreement, Royalty Obligation Expiration Period License Agreement, Royalty Obligation Expiration Period Defined benefit pension (loss) gain, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Federal Deferred Federal Income Tax Expense (Benefit) Schedule of Accrued and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Issuance of shares of Common Stock for services rendered Stock Issued During Period, Value, Issued for Services Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Changes in the obligations Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Measure: Measure [Axis] Additions related to current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year One Contingent consideration earned during the period but not yet paid Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration Liability, Consideration Earned Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination. Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Development and Regulatory Milestones Development and Regulatory Milestones [Member] Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved. Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Transfer of benefits net of payments from fund Defined Benefit Plan Benefit Obligation Transfer of Benefits Net Amount of benefit transfers received by defined benefit plan which increase benefit obligation. Income Tax, Examination [Table] Income Tax, Examination [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Finance lease right-of-use assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2024 Inducement Plan 2024 Inducement Plan [Member] 2024 Inducement Plan MINJUVI/MONJUVI MINJUVI/MONJUVI [Member] MINJUVI/MONJUVI Weighted Average Remaining Contractual Life (in years) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Number of entities determined to be VIEs Number Of Entities Determined To Be Variable Interest Entities Represents the number of Variable Interest Entities as on date. Funding of future development costs License Agreement Percentage of Future Global Development Costs Funded Represents the percentage of future global development costs funded under the license agreement. Loss on change in fair value of acquisition-related contingent consideration Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accumulated Other Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] 2028 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Cash and cash equivalents Asset Acquisition, Cash And Cash Equivalents Asset Acquisition, Cash And Cash Equivalents Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Net income per share Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] CMHSL CMSHL [Member] CMSHL Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Marketable securities Asset Acquisition, Marketable Securities Asset Acquisition, Marketable Securities Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Accrued and other liabilities Increase (Decrease) in Accrued Liabilities TABRECTA TABRECTA [Member] Represents information pertaining to TABRECTA, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14). Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Weighted-average fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Other Other Intangible Assets [Member] Income Taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four License agreement, termination period (in months) License Agreement, Termination Period License Agreement, Termination Period Uncured material breach, written notice period (in days) License Agreement, Written Notice Period For Uncured Material Breach License Agreement, Written Notice Period For Uncured Material Breach Schedule of Net of Compensation Expense, Across the Net Assets Acquired Asset Acquisition [Table Text Block] Schedule of Operating Loss Carryforwards Summary of Operating Loss Carryforwards [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Exercise Price Range [Axis] Exercise Price Range [Axis] Weighted average discount rate, operating leases Operating Lease, Weighted Average Discount Rate, Percent Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred revenue and accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Debt Instrument, Variable Rate Floor Debt Instrument, Variable Rate Floor Debt Instrument, Variable Rate Floor Credit Facility [Axis] Credit Facility [Axis] Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Foreign currency translation (loss) gain Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent State Deferred State and Local Income Tax Expense (Benefit) Fair Value as of Grant Date Award Grant Date Fair Value Foreign tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Customer Concentration Risk Customer Concentration Risk [Member] Achievement of Milestone [Axis] Achievement of Milestone [Axis] Represents information by different categories of achievement of milestones. Intrinsic value of vested options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Milestone payment, estimated useful life License Agreement Milestone Payment, Useful Life License Agreement Milestone Payment, Useful Life Geographical [Domain] Geographical [Domain] Schedule of Disaggregated Revenue Disaggregation of Revenue [Table Text Block] Intangible assets Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items] Represent Finite Lived And Indefinite Lived Intangible Assets By Major Class. Profit sharing from co-commercialization activities Collaborative Arrangement, Accounting Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.001 par value; 400,000,000 shares authorized; 193,434,305 and 224,286,862 shares issued and outstanding as of December 31, 2024 and 2023, respectively Common Stock, Value, Issued Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Expected contributions Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Number of shares available for grant for each award granted (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Number Of Shares Available For Grant For Each Award Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Number Of Shares Available For Grant For Each Award Granted Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Novartis And Lily Novartis And Lily [Member] Novartis And Lily In-process research and development assets Indefinite-Lived Intangible Assets Acquired Long term equity investments Equity Securities, FV-NI, Noncurrent Other Deferred Tax Assets, Other Accrued and Other Current Liabilities Accrued Liabilities, Current [Abstract] Merus Merus [Member] Represents information pertaining to Merus N. V. Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] 2029 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Concentration of risk Concentration Risk [Line Items] Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of December 31, 2024 and 2023 Preferred Stock, Value, Issued State and local income taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total gross deferred tax liabilities Deferred Tax Liabilities, Gross ADSs ADSs Represents American Depositary Shares. Basic (in dollars per share) Basic net income per share (in dollars per share) Earnings Per Share, Basic Cash paid for operating lease liabilities Operating Lease, Payments Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Long term investments Deferred Tax Assets, Investments Ownership [Domain] Ownership [Domain] Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Unpaid purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Property and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Finite-lived intangible assets: Finite-Lived Intangible Assets, Net [Abstract] Total current liabilities Liabilities, Current Share Repurchase Program [Axis] Share Repurchase Program [Axis] Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule of Fair Value of Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table] Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table] Represent Finite lived and indefinite lived intangible assets by major class. Eli Lilly Eli Lilly [Member] Represents details pertaining to Eli Lilly with whom we have entered into a License, Development and Commercialization Agreement. Loss contingences, gross to net deduction percentage (as percent) Loss Contingences, Gross To Net Deduction Percentage Loss Contingences, Gross To Net Deduction Percentage License Agreements License Agreements [Text Block] This element may be used to describe all significant license agreements of the reporting entity. Increase in deferred tax assets Deferred Tax Asset, Increase (Decrease), Amount Deferred Tax Asset, Increase (Decrease), Amount Employment period for eligibility to participate in the plan Share Based Compensation Arrangement by Share Based Payment Award, Employment Period to Participate under Plan Represents the period of employ after which an employee who works a minimum of 20 hours per week can participate under the plan. Acquisitions Business Combinations Policy [Policy Text Block] Discount rate (as percent) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Stock Compensation Share-Based Payment Arrangement [Text Block] Upfront payment Asset Acquisition, Consideration Transferred Entity Address, City or Town Entity Address, City or Town Lease Accounting Lessee, Leases [Policy Text Block] Schedule of Option Activity Under the 2010 Stock Plan Share-Based Payment Arrangement, Option, Activity [Table Text Block] Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Stock compensation expense Share-Based Payment Arrangement, Expense Interest and penalties as a component of income tax expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Loss Contingencies [Table] Loss Contingencies [Table] Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Assumed annualized forfeiture rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions Expected Annualized Forfeiture Rate Represents the expected annualized forfeiture rate for options granted. Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Finite-Lived Intangible Assets, Net Schedule of Finite-Lived Intangible Assets [Table Text Block] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] OPZELURA OPZELURA [Member] OPZELURA Foreign Foreign Tax Jurisdiction [Member] Maturity of our finance lease liabilities Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Revenues Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Regulatory Milestones Regulatory Milestones [Member] Represents information pertaining to certain regulatory events on the basis of which certain milestones are achieved. Development Milestones Development Milestones [Member] Represents information pertaining to certain development events on the basis of which certain milestones are achieved. Assets, Fair Value Disclosure Assets, Fair Value Disclosure Number of programs under the resulting products are co-funded for development Number of Programs Under Which The Resulting Products Are Co-Funded For Development Represents the number of programs in which the resulting products are co-funded for development. 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Finance lease liabilities Finance lease liabilities, current Finance Lease, Liability, Current Finished goods Inventory, Finished Goods, Net of Reserves Base Rate Base Rate [Member] Total lease cash payments Lessee, Operating Lease, Liability, to be Paid Insider Trading Arrangements [Line Items] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Licensed IP Intellectual Property [Member] Shelf life for finished goods inventory, maximum Inventory Finished Goods Useful Life Maximum Represents the maximum useful life of merchandise or goods held by the entity that are readily available for sale. Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Schedule of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Customer [Domain] Customer [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Subsidiary, ownership percentage, noncontrolling owner (as percent) Subsidiary, Ownership Percentage, Noncontrolling Owner Asset Acquisition Asset Acquisition [Domain] Exercise price, upper range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Schedule of Concentration of Credit Risk Related to Collaborative Partners Schedules of Concentration of Risk by Risk Factor Related to Collaborative Partners [Table Text Block] Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the collaborative partners. Collaboration Loss Sharing Collateralized Agreements [Abstract] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Other changes recognized in accumulated other comprehensive income (loss) Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Schedule of (Benefit) Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Changes in the Obligations and Plan Assets, the Funded Status and the Amounts Recorded Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name